You need to be logged in to use this feature.
The nominating institution CNRC on the project:
Shen offers a robust living cell platform that is widely accepted by regulatory authorities for manufacturing human vaccines. It has been used as a technology platform for development, and has potential for high-yield manufacturing of established vaccines or novel vaccines for emerging diseases, at a lower cost. This breakthrough will have a long-term impact.
Tags: Bio-Tech, COVID-19
Chun Fang Shen received his PhD in biochemical engineering from Western University in Canada before joining the National Research Council of Canada (NRC). During more than 20 years with the NRC, Shen has made significant contributions to the development of cell culture processes for the production of viral vectors and vaccines. He is currently a senior scientist with the NRC’s Human Health Therapeutics Research Centre.